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Abstract: Collagen is the most widespread extracellular matrix (ECM) protein in the body and is
important in maintaining the functionality of organs and tissues. Studies have explored interventions
using collagen-targeting tissue engineered techniques, using collagen hybridizing or collagen binding
peptides, to target or treat dysregulated or injured collagen in developmental defects, injuries,
and diseases. Researchers have used collagen-targeting peptides to deliver growth factors, drugs,
and genetic materials, to develop bioactive surfaces, and to detect the distribution and status of
collagen. All of these approaches have been used for various regenerative medicine applications,
including neovascularization, wound healing, and tissue regeneration. In this review, we describe in
depth the collagen-targeting approaches for regenerative therapeutics and compare the benefits of
using the different molecules for various present and future applications.
Keywords: collagen; extracellular matrix; tissue engineering; regenerative medicine; collagen
hybridizing peptide
1. Introduction
Collagen, the most abundant extracellular matrix (ECM) protein in mammals, regulates numerous
bodily processes, from the molecular to the macroscopic scale [1]. It also plays a large role in dictating
the overall mechanical and metabolic properties of tissues [1]. In many cases of developmental defects,
injuries, and diseases, collagen is observed to be injured or dysregulated [2]. Therefore, collagen could
be an ideal target for identifying and treating damaged sites. The study of native collagen in vivo
has recently expanded to explore diagnostics and therapeutics in disease models heavily influenced
by the abnormalities in collagen molecules and fibrils [3]. Molecules have been designed to bind
directly, or hybridize, to the collagen strands making the targeting of these abnormalities much more
feasible [4]. In this review, we further describe collagen’s structure-function relationship and its role in
developmental defects, injury, and disease. Then, we introduce the collagen-targeting molecules used
to date and the recent advances in their therapeutic and regenerative application.
2. Collagen in the Extracellular Matrix
2.1. Structure of Collagen
Collagen is a cell-responsive ECM protein that forms a tertiary structure capable of transferring
signals and mechanical stresses to cells, while protecting them from fatal loads [5]. The collagen
molecule is made up of three polypeptide chains intertwined to form a left-handed triple helical
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structure, via intra- and inter-chain hydrogen bonding. Each chain, termed an alpha chain, is made
up of a repeating sequence of three amino acids—Glycine-X-Y. Glycine is necessary in the repeating
amino acid sequence of collagen, due to its compact nature that enables the twisting of alpha chains
into the triple helix structure. X and Y are amino acid placeholders, most frequently proline and
hydroxyproline respectively, which dictate the mechanical and bioactive properties, and the exact steric
effects of the triple helix structure [2]. The alpha chains, ~300 nm in length, undergo a modification
process, including hydroxylation and glycosylation, to drive helix formation and transport, from the
rough endoplasmic reticulum to the Golgi bodies, and finally outside the cell to become part of the
ECM [2]. Collagen molecules are further arranged in a quasi-hexagonal crystal lattice and right-handed
supertwist to form microfibrils [6]. Microfibrils aggregate and interdigitate through covalent cross-links
to form a collagen fibril (ranging anywhere from 10–300 nm in diameter), which can be further aligned
with other collagen fibrils to create a collagen fiber [7].
There are various collagen types that differ based on the possible combinations of alpha helices
in the triple helix structure, which makes them tissue specific. To date, 27 types of collagen have
been distinguished in humans [2,8]. For instance, type I collagen, the most common type of collagen
occurring in ligaments, tendons, and muscles, is made up of two pro-alpha1 and one pro-alpha2 chains.
These procollagen alpha chains are coded by COL1A1 and COL1A2 genes, respectively. Conversely,
type II collagen is composed of three identical pro-alpha1 chains and occurs primarily in articular
cartilage [9]. Therefore, engineering approaches meant to regenerate collagen containing tissue, need
to account for the distinct biochemical and mechanical properties of the various types of collagen.
2.2. Biochemical and Mechanical Properties of Collagen
Although most tissues are composed of collagen, the diversity in type, amino acid sequence, and
cell-protein or protein-protein interactions vary the biochemical and mechanical properties of each
tissue, for optimal functionality. The subtle differences in properties affect the behaviors of cells in
states of homeostasis and regeneration or repair. For many natural regenerative processes in the body,
cells must be directed to repopulate at a defect site, recruit other cell types, and deposit ECM for organ
function restoration, post-injury. Collagen participates in the sequestration of growth factors and other
signaling molecules that aid in the paracrine regulation of cell behavior [10]. Several cell integrins
bind to collagen molecules and sequester growth factors, causing a cascade of signaling pathways
downstream to promote adhesion, proliferation, and differentiation [2].
Collagen is also heavily involved in mechanotransduction, affecting cell signaling pathways by
changing its stiffness and the force applied directly to the cells. Collagen has high tensile strength,
which allows it to transmit forces between tissues, while absorbing enough of a load to protect cells.
Making up over 70% of the ECMs of skin, tendon, and cartilage, the strength, stiffness, and Young’s
moduli of collagen molecules can significantly affect cell behavior and organ function [1,8]. Collagen
fibrils are largely anisotropic due to the individual collagen molecules aligning along their longitudinal
axis. This physical anisotropic nature of the molecules translates closely to a mechanical anisotropy of
the overall collagen fibrils [11]. This property serves as a benefit in many tissues that require higher
strengths and Young’s moduli (i.e., type I collagen’s moduli ranges from 5–11.5 GPa) in directions
specific for biological functions [11]. Other proteins also possess collagen binding domains (CBD)
that influence the cell behavior and physical properties of ECM. One example is glycosaminoglycans
(GAGs), which are present in many tissues and closely associated with collagen. These GAGs are
polysaccharides that have high negative charge densities and attract water to hydrate the tissues and
absorb the forces applied. Overall, many properties of tissue-specific ECMs dictate their function and
maintenance of a healthy phenotype, especially collagen’s biochemical and mechanical properties.
2.3. Role of Collagen in Developmental Defects, Injuries, and Diseases
Healthy collagen can positively promote migration, adhesion, and differentiation of cells to
guide morphogenesis in development as well as to regenerate tissues at injury or disease sites [12,13].
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However, collagen can also play an important role in developmental defects, injury, and disease.
Collagen dysregulation can lead to its over- or underproduction, which can severely impact specific
tissue functions. Excessive collagen remodeling, in diseases such as cancer or tissue fibrosis such as
kidney, heart, or pulmonary fibrosis, leads to a stiffened ECM significantly restricting the elasticity in
tissues that would normally need an elasticity factor, such as the lungs, muscles, and heart [14]. On the
other hand, injured or degraded collagen can weaken tissue mechanical integrity and reduce its ability
to sequester growth factors for differentiation or regenerative purposes, and respond to endogenous
signals from cells for optimal mechanotransduction [2]. The origin of dysregulated ECM collagen
can be hereditary, epigenetic, or environmental [15]. In all cases, understanding the role of collagen
in developmental defects, injuries, and diseases can help establish improved targeting mechanisms
designed for diagnostics, therapeutics, and regenerative purposes.
2.3.1. Developmental Defects
Collagen undergoes extensive proteolytic remodeling and organization during development [16,
17]. However, these processes can be stymied by genetic mutations that code for different collagen
types, which lead to a wide range of congenital defects. These mutations affect the biosynthesis and
processing of collagen from the amino acid sequence level to the tertiary structure level. Substitutions
can result in the replacement of a codon for a critical amino acid (i.e., glycine), within the alpha
chain, that prevents its propensity to form triple helices. Other deletions or insertions can affect
collagen-processing enzymes, which cleave terminal regions of procollagen strands and can thus change
the molecules’ solubility and/or properties. In developmental disease cases, such as osteogenesis
imperfecta, mutations primarily in the COL1A1 gene negatively impact the formation and folding
of alpha chains present in type I collagen, causing its excessive accumulation [18,19]. This causes a
downstream effect on triple helix formation and further processing that leads to a phenotype of brittle
bones, which can be lethal perinatally, in the most severe cases. Mutations observed in COL2A1 that
stunt formation of alpha chains in type II collagen result in weakened mechanical properties and
degraded cartilage tissue—a phenotype common in patients with chondrodysplasia [20]. Type IX
collagen mutations can change the amino acids in the X or Y position to tryptophan, which is not
naturally one of the amino acids in the sequence. Tryptophan does not allow for an ideal fit of alpha
chains in the triple helix, which leads to dysregulation of collagen and developmental defects [21].
This mutation appears as intervertebral disc disease in many patients [2].
2.3.2. Injuries
Environmental damage to collagen can take many forms. For instance, spinal cord injury is an acute
injury that results in the high accumulation of fibrotic tissue and scar formation if untreated. Post-injury,
a deposition of ECM meshwork, consisting primarily of type IV collagen, triggers inflammation and
prevents the regeneration of axons at the lesion center both by physical blockage and by presentation of
growth-inhibiting molecules [22]. This can cause any number of irreversible paralyses. Osteoarthritis is
a progressive degenerative disease originating from an acute injury to the joint cartilage, which sets off
type II collagen and general ECM breakdown. Breakage can occur on the order of collagen molecules
in the unraveling of alpha chains, or on the order of collagen fibrils leaving accumulated collagen
fragments at the injury site [2]. The degraded collagen at the injury site weakens its mechanical integrity.
This leaves the injury site vulnerable to further damage and eventual lifelong disability [23]. Injuries of
the anterior cruciate ligament also initiate rapid type I collagen turnover [24]. High enzymatic activity
and severe collagen remodeling cause delayed recellularization and lowered mechanical properties of
the regenerated tissue [25]. Collagen dysregulation takes a severe toll on tissues that mainly provide
structural and mechanical stability, and acute injury that initiates this phenomenon can contribute to
lifelong disability and chronic disease.
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2.3.3. Diseases
Disease can instigate the fibrosis or degradation of tissue which is primarily made up of ECM
collagen. In the prevalent condition of atherosclerosis, fat and plaque buildup lead to thrombotic
occlusion in vessel walls [26]. Not only is collagen damaged at the onset of this condition, but it
is further damaged from the exposure to blood flow after a balloon angioplasty that corrects for
the atherosclerosis and myocardial infarction (MI). Although cell binding sites allow collagen to
aid in the regeneration of damaged tissues, exposed collagen in vessels can lead to a buildup of
collagen-bound platelets causing the narrowing of vasculature and eventual thrombosis [27]. Cancers
also possess a phenotype of dysregulated collagen often in the form of excessively remodeled ECM
and fibrotic tissue [28]. Different cancers remodel various collagen types including medulloblastoma
(type I collagen) [29], pancreatic cancer (type IV collagen) [30], epithelial ovarian cancer (type I and
III collagen) [31], breast cancer (type I collagen) [28], and colorectal cancer (type VIII collagen) [32].
Though cardiovascular disease and cancer are two of the most common causes of death in the United
States, other diseases, such as pulmonary, liver, and kidney fibrosis also suffer from dysregulation
and chronic overproduction of collagen and other ECM proteins [4,33]. Tissue fibrosis often results in
permanent scarring, organ malfunction and, ultimately death if untreated [4]. Due to its predominant
role in ECM degradation, remodeling, and fibrosis, collagen provides the perfect target for new and
widespread diagnostic, therapeutic, and regenerative technologies. To date, several molecules have
been identified to specifically target collagen for diagnostic and therapeutic purposes. The subsequent
sections further describe these molecules and their potential use in treatment of the above diseases in
the form of tissue regeneration.
3. Collagen-Targeting Molecules
Targeting collagen has a widespread potential in understanding, diagnosing, and treating
developmental defects, injuries, and diseases. We will discuss the various peptides derived from
collagen binding domains, the antibodies designed to bind collagens at different statuses, and the
collagen mimetic peptides that hybridize to the denatured collagen strands. The peptides range
from 7–30 amino acids in length and target many types of collagen [4]. They have been primarily
used in conjunction with growth factors and drugs to promote regeneration of blood vessels, bone,
and cartilage. These functionalizations are detailed in subsequent sections.
3.1. Collagen Binding Peptides
3.1.1. SILY
The peptide, RRANAALKAGELYKCILY, is derived from the platelet receptor that binds to α1
chains in collagen. The original molecule was discovered through the purification of platelet membrane
receptors and competitive binding assays to α1 chains and type I fibrillar collagen [34]. More recently,
the peptide has been altered at its internal cysteine, replacing the thiol group for cysteine with a hydroxyl
group for serine [34]. Although the new molecule, RRANAALKAGELYKSILYGC (Kd = 0.86 µM),
abbreviated to SILY, has a slightly lower binding affinity to type I collagen than its original counterpart,
it has enabled the chemical conjugation of SILY to other molecules, primarily a large dermatan sulfate
(DS) molecule [34]. Even though SILY has been noted with relatively limited binding specificity to
collagen (personal communication with researchers in the field), its high binding affinity to collagen has
led to extensive medical applications. Specifically, DS-SILY acts as a biomimetic of decorin, a natural
proteoglycan that consists of a glycosaminoglycan (GAG) chain and a protein core, rich in leucine
repeats that aid in the binding to type I collagen fibrils [34,35]. In cases of vessel injury or balloon
angioplasty, endothelialization can be damaged and collagen exposed. This can lead to the buildup of
collagen-bound platelets and restenosis of vessels [36]. The conjugated molecule competitively binds
to the platelet binding sites, which reduces the potential for thrombosis [37]. DS-SILY has been shown
to inhibit platelet accumulation and matrix metalloproteinase (MMP)-mediated collagen degradation
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as well as to reduce the effects of pro-inflammatory and pro-fibrotic factors, platelet-derived growth
factor (PDGF) and interferon-γ (IFN-γ), which typically activate smooth muscle cell proliferation and
migration to cause intimal hyperplasia [35,37–40].
3.1.2. TKKTLRT
TKKTLRT is a peptide derived from the CBD in the collagen-degrading enzyme, collagenase [4].
The molecule was constructed from the complementary nucleotide sequence on interstitial collagen
that codes for the region cleaved by the enzyme. Original reasons for this peptide’s synthesis were not
for targeting collagen, but for inhibiting collagenase activity [41]. Collagenase can negatively impact
the native ECM by breaking down collagen to cause excessive remodeling (e.g., cancer) or progressive
degradation (e.g., osteoarthritis) in vivo [42,43]. Tissue inhibitors of metalloproteinase (TIMP) have
been discovered to bind directly to collagenase molecules and prevent further cancer metastasis as ECM
remodeling is a common phenotype of cancer because it enables cancer cell migration [43]. However,
these TIMP molecules only target collagenase therefore reducing their applicability for regenerative
use in sites of damaged tissue. TKKTLRT not only competitively binds to type I collagen with high
specificity, which decreases the likelihood of collagenase-based degradation, but can be functionalized
to deliver factors to stimulate regeneration of tissue in areas of dysregulation. To date, TKKTLRT has
been conjugated to several growth factors and drugs to facilitate diabetic wound healing, neurogenesis,
vascularization, and cellularization [27,44–48]. Subsequent sections will detail the specific nature of
these functionalizations to promote tissue regeneration.
3.1.3. WREPSFMALS
WREPSFMALS is a peptide derived from the von Willeband’s factor (vWF), which is an adhesive
glycoprotein found in plasma, platelets, and endothelial cells [49]. vWF is heavily involved in
clotting processes, interacting closely with factor VIII to control wound healing [50]. In cases similar
to the previously described vessel damage due to myocardial infarction and balloon angioplasty,
platelets can aggregate where collagen is exposed [36]. WREPSFMALS competitively binds to collagen,
which mediates platelet adhesion and clotting, and reduces the likelihood of thrombosis [49,50].
This decapeptide primarily targets type I collagen but has also been shown to bind other types of
collagen (e.g., type II) [49]. It binds to intact collagen and denatured collagen (i.e., gelatin) with
lower binding affinities (Kd = 100 µM) and specificities than TKKTLRT (Kd < 100 µM) [44,45].
To date, WREPSFMALS has been used to improve vascularization and cellularization. It has also been
conjugated to growth factors to improve diabetic wound healing and regeneration of the intestine [45,51].
Subsequent sections further describe the strategies used in conjunction with this peptide to promote
tissue regeneration.
3.2. Collagen-Targeting Antibodies
Collagen-labeling antibodies have been designed to specifically target denatured collagen and
generally inhibit tumor growth, to prevent further degenerative progression of cancer [52,53]. These
monoclonal antibodies provide an advantage over collagen-binding peptides because the peptide
molecules have a limited propensity to bind denatured collagen over intact collagen. For conditions
where collagen molecules are denatured or excessively remodeled (e.g., osteoarthritis, cancer, etc.),
these collagen-binding peptides fall short in their binding affinities. While these antibodies have
a superior targeting specificity, they are limited in their sensitivity to certain types of collagen and
methods of collagen denaturation (i.e., thermal, enzymatic, physical, etc.) [4]. Antibodies mAb HUIV26
and D93 (Kd = 6.5 µM) both target cryptic epitopes on type IV collagen that are exposed by the
denaturation of collagen. Monoclonal antibody, mAb HUIV26, targets thermally denatured collagen to
inhibit tumor growth whereas D93 can target both thermally and proteolytically (i.e., MMP) denatured
collagen to inhibit tumor growth [52,53]. Since developmental defects, injuries and diseases undergo
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different modes of collagen denaturation, antibodies may not have as wide a range of applications in
targeting collagen for tissue engineering.
3.3. Collagen Hybridizing Peptides and Collagen Mimetic Peptides
To address the disadvantages of previously described collagen-binding peptides and antibodies,
researchers have developed a collagen mimetic peptide capable of hybridizing to any individual
alpha chain that has unraveled from the normal tightly bound triple helix structure of collagen [54].
This molecule offers a technology that has specificity to denatured collagen and is broadly applicable
for different collagen types and denaturation processes.
Collagen hybridizing peptide (CHP) is comprised of the repeating amino acids glycine, proline,
and hydroxyproline, which match native collagen’s main repeating amino acid sequence and allow
for strong and highly specific hybridization to denatured collagen strands. Formally known as
collagen mimetic peptide (CMP), which ranges from 6–10 amino acid sequence repeats, CHP has
been standardized to represent (Gly-Pro-Hydroxypro)9. Other forms of CMP have substituted
hydroxyproline for another proline, but it has since been shown that hydroxyproline increases the
stability of the triple helix structure by enabling the formation of additional stabilizing hydrogen
bonds [55]. The high propensity to form triple helices gives the CHP molecule an advantage in
locating areas of protein dysregulation and detecting diseases in the early stages. CHP offers an
additional advantage to other collagen binding peptides by binding specifically to the denatured
collagen molecules, in preference to intact collagen.
CHP’s tendency to assemble into triple helices makes it naturally self-assemble in solution, prior
to use, which keeps it from hybridizing to the desired collagen. To resolve this issue, three main
treatments have been developed. CHP’s binding affinities are heat sensitive so one method is to heat
up the solution and then quench to room temperature before application to a tissue [56]. Another
method involves physically attaching a photocleavable nitrobenzyl group to a center glycine in the CHP
molecule to create bulky steric effects and prevent self-assembly. The application of UV light cleaves the
caged CHP molecule to enable collagen-targeting [57]. Most recently, a third method utilizes a similar
physical addition to the CHP molecule to hinder self-assembly and create steric repulsion between
injected molecules. Each proline of the CHP molecule was replaced with a (2S,4S)-4-fluoroproline (f)
residue. This altered the previously stable steric effects of proline and neighboring hydroxyproline
residues of CHP molecules while maintaining hybridization capabilities with natural collagen chains
that are not as rich in hydroxyproline (occurring only in 34% of Gly-X-Y triplets) [58,59].
At its inception, CHP was a functional diagnostic marker of disease and injury sites
and a method for studying embryonic development and aging. It was conjugated to a
fluorescent marker (carboxyfluorescein) to reveal both denatured and highly remodeled collagen
in diseases such as osteoarthritis, myocardial infarction, glomerulonephritis, pulmonary fibrosis,
and Marfan syndrome [4,17,57]. The most recent alteration of CHP that exchanges proline with
(2S,4S)-4-fluoroproline (f) residues has also provided another mechanism by which to diagnose
collagen dysregulation through fluorescent imaging [58]. CHP also has the potential to increase the
efficiency of regenerative factor delivery, to optimize localization and minimize non-specific binding.
CHP also binds to all types of collagen, as opposed to collagen-binding peptides that target a particular
collagen type. While other collagen-binding peptides may possess a type-specific binding domain,
CHP hybridizes to any triple helix structure of collagen molecules making it a peptide that can be
widely used for different diseases, injuries, and congenital defects [17]. However, since CHP can
bind to any denatured triple helix structure, it would not have the specificity to hybridize to certain
denatured collagen types. In the case of spinal cord injury, delivering signals to aid in the regeneration
of vasculature, muscle, bone and neural tissues would require a multitude of signals. For this reason,
the type-sensitive collagen-targeting molecules may provide a competitive advantage to CHP in
certain cases.
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4. Strategies for Targeting Collagen in Regenerative Medicine and Tissue Engineering
4.1. Delivery of Biologic Drugs/Growth Factors
Collagen-rich ECM functions as more than just the mechanical structure supporting cells in vivo.
The ECM interacts with cells in various ways, through binding domains and sequestered growth
factors. As a framework made up of a diverse set of proteins, there are many opportunities for cells
to bind to different binding domains, take up sequestered growth factors or immobilized drugs, and
respond to mechanical cues prompted by the stiffness, stress relaxation or other mechanical properties
of ECM. The advantage of delivering exogenous growth factors to diseased or injury sites is that they
mimic the bioactive cues normally supplied by healthy ECM to sequester growth factors and control
mechanical, biochemical, and metabolic properties of tissue. Approaches that provide these signals fall
under the term developmental tissue engineering, where it is believed that restoring the endogenous
signals to match growth factors sequestered by healthy ECM will aid in the full regeneration of tissue.
Delivery of those cues as well as biologic drugs, however, have so far been non-specific and short-term.
Collagen binding and hybridizing peptides have thus improved the affinity, specificity, and lifetime
of growth factors and drugs binding to collagen [60]. In several studies, drugs and growth factors
were conjugated to targeting molecules to drive angiogenesis, wound healing, and musculoskeletal
tissue regeneration.
SILY has been commonly conjugated to DS to inhibit platelet accumulation in damaged blood
vessels [37]. SILY has also been fused with growth factors to add a regenerative function to the
collagen-binding peptide. Mussel adhesive protein (MAP), derived from the marine mussel, has
special adhesive properties that aid in scarless skin regeneration [61]. It has been fused to SILY to
target the overproduction of collagen present in scars. CBD-MAP was tested in a wound healing
assay and surgical procedure where it showed promise in serving as collagen-targeting glue [62].
SILY has also been conjugated to nanoparticles (NP) loaded with peptide KAFAK, designed to
inhibit mitogen-activated protein kinase activated protein kinase 2 (MK2) activity effectively reducing
pro-inflammatory cytokine levels. This complex of peptides and particles were able to modulate the
platelet accumulation and immune response commonly seen after blood vessel damage [63].
TKKTLRT has been used to provide a targeting functionality to several growth factors and drugs
to promote angiogenesis, wound healing, and bone regeneration [27,44–46]. TKKTLRT was fused
with vascular endothelial growth factor (VEGF165) to add a collagen-targeting property to the growth
factor. The fusion peptide (CBD-VEGF) was then immobilized onto a collagen hydrogel and implanted
subcutaneously in a mouse model to demonstrate improved vascularization [27]. The pair was then
tested, through intracardiac injection, into the right ventricle of a mouse post-MI. Improved cardiac
function was observed when compared to saline and plain VEGF injections, based on the low percentage
of scar tissue and increased wall thickness in the infarct area [27,45]. Further applications with this
collagen-targeting VEGF include implantation of a functionalized collagen hydrogel in a diabetic mouse
model, demonstrating a higher wound healing rate, better vascularization, and a higher level of VEGF
in the granulation tissue wound [46]. Fusion of TKKTLRT with stromal cell-derived factor-1α (SDF-1α)
in another study of MI observed that the recombinant chemokine improved recruitment of stem cells
to the ischemic heart promoting healthier cardiac function [34]. Several other growth factors have been
fused with TKKTLRT including bFGF and BMP-2 for wound healing (e.g., uterine horn reconstruction,
bladder regeneration, etc.) and mineralized bone matrix regeneration, respectively [45]. Dai et al.
created a fusion molecule between CBD (TKKTLRT) and a fragment of cetuximab, an anti-epidermal
growth factor receptor (EGFR) antibody [47]. These studies allowed for the sustained release of the
drug from a collagen scaffold for improved endogenous neurogenesis for acute spinal cord injury [48].
WREPSFMALS has also been fused with similar growth factors to TKKTLRT, but targets a different
binding site on collagen and binds with a lower affinity. These growth factors include bFGF, BMP-2 and
EGF to regenerate many tissues for diabetic wounds and mature bone (with trabeculae, and medullar
cavities and blood vessels) [45,51].
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4.2. Delivery of Peptides
A different collagen-targeting approach to tissue regeneration and immobilization of growth
factors has been shown using CHP molecules conjugated to various peptides. CHP was attached to a
pro-angiogenic cell-binding domain of VEGF termed QK. The CHP-QK molecules efficiently hybridized
to hydrogels with varying degrees of denatured collagen (i.e., gelatin) and to poly (ethylene glycol)
diacrylate hydrogels functionalized with other CHP molecules [64]. Substance P (Sub P) is a peptide
that binds to the nerve receptor neurokinin and regulates vasodilation, angiogenesis, and immune
responses. Sub P has also been shown to improve the proliferation of fibroblasts and epithelial tissue,
which demonstrates its application for wound healing. Sub P was added to CHP to improve targeted
wound healing of damaged collagen [65]. In these studies, endothelialization and neovascularization
were achieved more efficiently in sites of degraded collagen and posed a competitive approach to
presenting soluble growth factors to diseased tissue [64,66]. It also allows the delivery method to
be modified from a local injection to an intravenous injection since CHP would not hybridize to any
intact collagen on the way to the injury site. Tetsuji Yamaoka’s research lab has also used the collagen
hybridizing sequence modified with integrin α4β1 ligand, REDV (POG7G3REDV) for vascular graft
application [67,68]. This study showed that integrin-mimicking peptides have the potential to recruit
host cells for many purposes including re-endothelialization of grafts [67].
Functionalization of the collagen-targeting molecules is still in the early stages of its application
for regenerative purposes (Table 1). Immobilizing drugs, growth factors, and peptides to scaffolds
and damaged sites in the body holds much potential in the field of regenerative medicine. Collagen
binding and hybridizing molecules are advantageous in their use when combined with regenerative
factors. There is promise in expanding the pool of molecules used and improving the collagen-targeting
strategies for specific regenerative applications.




Target Functional Group Regenerative Application Ref.
CHP dn-Col QK Angiogenesis [64,66]
SubP Wound healing [65]
SILY Type I Col MAP Scarless skin regeneration [62]
KAFAK-loaded NP Anti-inflammatory regulation [63]






BMP-2 Mineralized bone matrixregeneration [45]
WREPSFMALS Type I Col EGF Intestinal crypt regeneration [45]
bFGF Diabetic wound healing [51]
BMP-2 Mature bone regeneration [45]
POG7G3REDV
(CMP7)
dn-Col REDV Endothelialization [67,68]
mAb HUIV26 Thermallydn-Col IV n/a Inhibition of tumor growth [53]
D93 Enzymaticallydn-Col IV n/a Inhibition of tumor growth [52]
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4.3. Development of Bioactive Surfaces
The application of tissue engineering approaches to regenerative medicine often involves the use
of biomaterial hydrogels and scaffolds, made with either naturally sourced or synthetic materials [69].
One of the benefits of naturally derived constructs is that they contain at least some inherent
cell-interactive properties, but they fall short in studies that require an independent control of
properties (e.g., decoupling mechanical and biochemical properties) [70]. Synthetically derived
scaffolds have the advantage of having independently tunable properties, but remain inert to their
host cells and prevent the natural integration with the host tissue. Because the synthetic biomaterial
can sometimes be hydrophobic, the scaffold risks high levels of surface protein adsorption. These
hydrophobic surfaces can expose platelet binding regions on the adsorbed proteins, causing unwanted
clotting and eventual fibrous encapsulation that naturally occurs when the body’s immune system
senses foreign material [71]. Ideally, tissue engineered constructs should be tunable in every property
so that scaffolds can be appropriately designed for various applications, but would also possess
the ability to integrate with the host tissue and trigger minimal immune responses [72]. Several
collagen-targeting molecules, specifically CHP, have been conjugated to otherwise inert biomaterials
for these regenerative purposes (Table 2).




Biomaterial Regeneration Application Ref.
CHP dn-Col PEGDA Angiogenesis [66]
PV membranes Chondrogenesis [73]
PEODA Chondrogenesis [74]
CMPX-PEGDA dn-Col Collagen film
Spatio-temporal bioactive factor
release for tissue repair [75]
Studies have explored functionalizing synthetic scaffolds with CHP to aid in host ECM integration
and to promote cell adhesion through ECM deposition. In conjugating CHP to poly (ethylene
glycol) diacrylate hydrogels, researchers could drive capillary formation using the CHP-modified
VEGF-mimetic peptide, CHP-QK [64]. CHP’s propensity to hybridize to other CHP strands allowed the
mimicking of collagen molecules to target synthetic implants. Angiogenesis was improved in the burn
wounds of a mouse model when tunable synthetic biomaterials had immobilized bioactive CHPs [66].
Poly (ethylene oxide) diacrylate (PEODA) hydrogels and PV membranes were also functionalized
with CHP to better differentiate mesenchymal stromal cells (MSCs) toward a chondrogenic phenotype,
and thus improve chondrogenesis. It was presumed that the functionalization allowed cell deposition of
collagen and associated GAGs for improved mechanical support-an essential aspect of the chondrocytes’
microenvironment [73,74]. CHP was also used to create gradients both spatially and temporally on
surfaces to drive regenerative processes that rely heavily on gradients. Varying the chain length of
CMPs changed the propensity to form triple helix and therefore affected CMPs’ affinities to bind
collagen film [75]. These techniques built off previous studies that functionalized biomaterials with
drugs (e.g., drug-eluting stents) to provide a competitive aspect of spatial and temporal control—two
parameters that hold important roles in general tissue regeneration.
4.4. Detection of Collagen Damage in Decellularized ECM Scaffolds
A common tissue engineered construct used for regenerative purposes is a decellularized ECM
scaffold of desired tissues [76]. There are several benefits of using the natural ECM as a physical niche
for regenerating diseased tissue. Natural ECMs match the exact protein makeup of healthy tissues in
particular locations. They are also bioactive constructs containing cell binding domains, which drive
cell adhesion, proliferation, differentiation, migration, and many other cell behaviors. Furthermore,
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the mechanical properties of natural ECMs allow transmission of precise mechanical cues to native
cells for optimal function and regeneration [77].
Researchers have explored many decellularization techniques, with the intention of recellularizing
and re-implanting ECMs in a diseased or injured site for regeneration [78–80]. These techniques
can use physical, chemical, or enzymatic methods to detach and eliminate all cellular components
prior to recellularization [81]. They also range in harshness, which can pose obstacles regarding
the preservation of structural integrity, protein degradation, and loss of bioactive factors [82–86].
These cell-interactive and cell-responsive aspects of the decellularized ECM give it a competitive
advantage over many other natural or synthetic engineered scaffolds so they cannot be sacrificed
during the decellularization process itself [87]. Hwang et al. used CHP to assess damage to the ECM
morphology after different chemical decellularization methods were performed [88]. A fluorescently
tagged CHP molecule was used to label denatured collagen in porcine urinary bladders and porcine
cruciate ligaments split into four experimental groups and treated with four detergents often used
in decellularization methods (Triton X-100, SDS, SD, CHAPS). The authors found SDS to be harshest
on the collagen molecular structure, followed by Triton X-100. While SD and CHAPS also appeared
to alter ECM morphology, these groups were only affected on a macroscopic scale showing changes
to collagen’s fibrillar structure. Both types of modifications to the ECM structure could have lasting
effects on its mechanical integrity and bioactive features [88].
It is crucial to have a mechanism like CHP for observing the structure and dysregulation of collagen
during technical procedures and for providing the best chance of success for regenerating tissues
in vivo. Not only can this technique identify superior chemicals for decellularization, but it has the
potential to be used in vivo to assess ECM turnover after collagen-based scaffolds are implanted [89].
4.5. Delivery of Genetic Materials
Drug and gene delivery methods have been used in attempts at reducing ECM-mediated fibrosis
and the general overproduction of collagen. However, they have fallen short in their targeting ability
thus far. The benefits of using gene delivery, rather than high doses of growth factors, are the sustained
release of plasmids, efficient transfection due to local and specific delivery, and lower chance of
tumor/cancer development [55,90]. Incorporating a collagen-targeting aspect to gene delivery may
pose a competitive technique for delivering genetic materials, such as plasmids, to collagen rich tissues
and treating diseases. Some chemical modifications of collagen can influence collagen’s biochemical
and mechanical properties through the blocking of binding domains. Therefore, CMPs hold great
benefits due to their hybridization to denatured collagen strands without chemically modifying the
collagen molecules. Furthermore, the efficiency of covalent chemical binding is low, due to the
complexity of collagen’s tertiary structure. CMPs were used to immobilize DNA polyplexes containing
pMV-GLuc plasmid on collagen films and hydrogels. CMPs maintained a sustained release of plasmid
for over 2 weeks—longer than the usual time scale of hours for genes to diffuse out of constructs [55].
Cells were able to take up genes with a higher transfection efficiency measured by a higher Caveolin-1
silencing effect reported in one study [90]. In this study, gene delivery using CMPs proved a competitive
approach to delivering immobilized, or soluble, growth factors to engineered constructs and other
regenerative techniques.
This technology is tailorable to regenerative applications and can improve the long-term
regenerative effects on injured tissue. In other technologies developed for regenerative purposes,
biomaterial implants may induce inflammatory responses and delivering growth factors may only
have temporary effects. Gene therapy provides the unique ability to change natural processes to
promote long-term regeneration effects and can be a cheaper and more stable approach over delivery of
growth factors [90]. Although many genes have not been explored as targets for this collagen-targeting
system, many have the potential to improve angiogenesis, wound healing, and treat hereditary and
developmental diseases.
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5. Conclusions and Future Therapeutic Applications of Collagen-Targeting Molecules
Collagens play a very significant role in the regulation of developing and maintaining healthy
tissues. Collagens are a key component of the extracellular matrix in most tissues and can be a main
identifier of diseased tissue when dysregulated. Though extensive research has worked on targeting
collagen for regenerative and therapeutic efforts, this field has not been thoroughly exhausted in its
applicability. Beginning as a method for diagnostics in fibrotic and degraded tissue diseases and a
technology for studying early development, collagen-targeting strategies have expanded to therapeutic
approaches such as delivering and immobilizing growth factors and genetic materials for disease
treatment [4,45]. There are future promising opportunities to deliver a wide range of materials via
collagen-binding or hybridizing peptides. Modifications of cell membranes, exosomes, drugs or
specific cell-binding peptides with these targeting molecules can further drive and localize regeneration
in a more thorough approach. Functionalizations can be used to further explore therapeutics for
other diseases and developmental defects including atherosclerosis, myocardial infarction, pulmonary
fibrosis, cirrhosis, and spina bifida [4]. Not only will collagen-targeting strategies be used for more
regenerative applications, but there are also opportunities to better understand the fundamental
mechanisms of developmental defects, injury, and disease, as well as to be potentially applied for
personalized medicine and drug screening applications. With so many possible applications of
these technologies, it is important to better understand the mechanisms and differences of these
collagen-targeting molecules and the feasible functionalizations that could improve the effectiveness of
tissue regeneration.
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vWF von Willeband’s factor
TIMP Tissue inhibitors of metalloproteinase
CHP Collagen hybridizing peptide
CMP Collagen mimetic peptide
MAP Mussel adhesive protein
NP Nanoparticles
bFGF Basic fibroblast growth factor
VEGF Vascular endothelial growth factor
MK2 Mitogen-activated protein kinase activated protein kinase 2
SDF-1α Stromal cell-derived factor-1α
QK VEGF mimetic peptide
Sub P Substance P
EGF Epidermal growth factor
EGFR Epidermal growth factor receptor
PEGDA Poly(ethylene glycol) diacrylate
PV Poly(vinyl alcohol)
PEODA Poly(ethylene oxide) diacrylate
PLGA Poly(lactide-co-glycolide)
MSC Mesenchymal stromal cell
pMV-GLuc Portal-mesenteric vein glucose
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